375 related articles for article (PubMed ID: 33336228)
1. Polygenic Risk Scoring is an Effective Approach to Predict Those Individuals Most Likely to Decline Cognitively Due to Alzheimer's Disease.
Daunt P; Ballard CG; Creese B; Davidson G; Hardy J; Oshota O; Pither RJ; Gibson AM
J Prev Alzheimers Dis; 2021; 8(1):78-83. PubMed ID: 33336228
[TBL] [Abstract][Full Text] [Related]
2. Utility of Polygenic Risk Scoring to Predict Cognitive Impairment as Measured by Preclinical Alzheimer Cognitive Composite Score.
Gao Q; Daunt P; Gibson AM; Pither RJ;
JAR Life; 2022; 11():1-8. PubMed ID: 36923235
[TBL] [Abstract][Full Text] [Related]
3. Utility of an Alzheimer's Disease Risk-Weighted Polygenic Risk Score for Predicting Rates of Cognitive Decline in Preclinical Alzheimer's Disease: A Prospective Longitudinal Study.
Porter T; Burnham SC; Milicic L; Savage G; Maruff P; Lim YY; Li QX; Ames D; Masters CL; Rainey-Smith S; Rowe CC; Salvado O; Groth D; Verdile G; Villemagne VL; Laws SM;
J Alzheimers Dis; 2018; 66(3):1193-1211. PubMed ID: 30412495
[TBL] [Abstract][Full Text] [Related]
4. Polygenic hazard score: an enrichment marker for Alzheimer's associated amyloid and tau deposition.
Tan CH; Fan CC; Mormino EC; Sugrue LP; Broce IJ; Hess CP; Dillon WP; Bonham LW; Yokoyama JS; Karch CM; Brewer JB; Rabinovici GD; Miller BL; Schellenberg GD; Kauppi K; Feldman HA; Holland D; McEvoy LK; Hyman BT; Bennett DA; Andreassen OA; Dale AM; Desikan RS;
Acta Neuropathol; 2018 Jan; 135(1):85-93. PubMed ID: 29177679
[TBL] [Abstract][Full Text] [Related]
5. Comparison of CSF markers and semi-quantitative amyloid PET in Alzheimer's disease diagnosis and in cognitive impairment prognosis using the ADNI-2 database.
Ben Bouallègue F; Mariano-Goulart D; Payoux P;
Alzheimers Res Ther; 2017 Apr; 9(1):32. PubMed ID: 28441967
[TBL] [Abstract][Full Text] [Related]
6. Alzheimer's Disease Assessment Scale-Cognitive subscale variants in mild cognitive impairment and mild Alzheimer's disease: change over time and the effect of enrichment strategies.
Podhorna J; Krahnke T; Shear M; Harrison JE;
Alzheimers Res Ther; 2016 Feb; 8():8. PubMed ID: 26868820
[TBL] [Abstract][Full Text] [Related]
7. Association Between Polygenic Risk Score and the Progression from Mild Cognitive Impairment to Alzheimer's Disease.
Liu H; Lutz M; Luo S;
J Alzheimers Dis; 2021; 84(3):1323-1335. PubMed ID: 34657885
[TBL] [Abstract][Full Text] [Related]
8. Amyloid-β and APOE genotype predict memory decline in cognitively unimpaired older individuals independently of Alzheimer's disease polygenic risk score.
Tomassen J; den Braber A; van der Lee SJ; Reus LM; Konijnenberg E; Carter SF; Yaqub M; van Berckel BNM; Collij LE; Boomsma DI; de Geus EJC; Scheltens P; Herholz K; Tijms BM; Visser PJ
BMC Neurol; 2022 Dec; 22(1):484. PubMed ID: 36522743
[TBL] [Abstract][Full Text] [Related]
9. Prediction of Cognitive Decline for Enrichment of Alzheimer's Disease Clinical Trials.
Tam A; Laurent C; Gauthier S; Dansereau C
J Prev Alzheimers Dis; 2022; 9(3):400-409. PubMed ID: 35841241
[TBL] [Abstract][Full Text] [Related]
10. Effect of amyloid on memory and non-memory decline from preclinical to clinical Alzheimer's disease.
Lim YY; Maruff P; Pietrzak RH; Ames D; Ellis KA; Harrington K; Lautenschlager NT; Szoeke C; Martins RN; Masters CL; Villemagne VL; Rowe CC;
Brain; 2014 Jan; 137(Pt 1):221-31. PubMed ID: 24176981
[TBL] [Abstract][Full Text] [Related]
11. Application of Digital Cognitive Biomarkers for Alzheimer's Disease: Identifying Cognitive Process Changes and Impending Cognitive Decline.
Bock JR; Hara J; Fortier D; Lee MD; Petersen RC; Shankle WR
J Prev Alzheimers Dis; 2021; 8(2):123-126. PubMed ID: 33569557
[TBL] [Abstract][Full Text] [Related]
12. Design and first baseline data of the DZNE multicenter observational study on predementia Alzheimer's disease (DELCODE).
Jessen F; Spottke A; Boecker H; Brosseron F; Buerger K; Catak C; Fliessbach K; Franke C; Fuentes M; Heneka MT; Janowitz D; Kilimann I; Laske C; Menne F; Nestor P; Peters O; Priller J; Pross V; Ramirez A; Schneider A; Speck O; Spruth EJ; Teipel S; Vukovich R; Westerteicher C; Wiltfang J; Wolfsgruber S; Wagner M; Düzel E
Alzheimers Res Ther; 2018 Feb; 10(1):15. PubMed ID: 29415768
[TBL] [Abstract][Full Text] [Related]
13. Association Between Elevated Brain Amyloid and Subsequent Cognitive Decline Among Cognitively Normal Persons.
Donohue MC; Sperling RA; Petersen R; Sun CK; Weiner MW; Aisen PS;
JAMA; 2017 Jun; 317(22):2305-2316. PubMed ID: 28609533
[TBL] [Abstract][Full Text] [Related]
14. Plasma Aβ42/40 Ratio Detects Early Stages of Alzheimer's Disease and Correlates with CSF and Neuroimaging Biomarkers in the AB255 Study.
Pérez-Grijalba V; Romero J; Pesini P; Sarasa L; Monleón I; San-José I; Arbizu J; Martínez-Lage P; Munuera J; Ruiz A; Tárraga L; Boada M; Sarasa M
J Prev Alzheimers Dis; 2019; 6(1):34-41. PubMed ID: 30569084
[TBL] [Abstract][Full Text] [Related]
15. Blood phosphorylated tau 181 as a biomarker for Alzheimer's disease: a diagnostic performance and prediction modelling study using data from four prospective cohorts.
Karikari TK; Pascoal TA; Ashton NJ; Janelidze S; Benedet AL; Rodriguez JL; Chamoun M; Savard M; Kang MS; Therriault J; Schöll M; Massarweh G; Soucy JP; Höglund K; Brinkmalm G; Mattsson N; Palmqvist S; Gauthier S; Stomrud E; Zetterberg H; Hansson O; Rosa-Neto P; Blennow K
Lancet Neurol; 2020 May; 19(5):422-433. PubMed ID: 32333900
[TBL] [Abstract][Full Text] [Related]
16. Polygenic effects on the risk of Alzheimer's disease in the Japanese population.
Kikuchi M; Miyashita A; Hara N; Kasuga K; Saito Y; Murayama S; Kakita A; Akatsu H; Ozaki K; Niida S; Kuwano R; Iwatsubo T; Nakaya A; Ikeuchi T; ;
Alzheimers Res Ther; 2024 Feb; 16(1):45. PubMed ID: 38414085
[TBL] [Abstract][Full Text] [Related]
17. Hypothetical Preclinical Alzheimer Disease Groups and Longitudinal Cognitive Change.
Soldan A; Pettigrew C; Cai Q; Wang MC; Moghekar AR; O'Brien RJ; Selnes OA; Albert MS;
JAMA Neurol; 2016 Jun; 73(6):698-705. PubMed ID: 27064267
[TBL] [Abstract][Full Text] [Related]
18. Identification of prognostic factors to predict cognitive decline of patients with early Alzheimer's disease in the Japanese Alzheimer's Disease Neuroimaging Initiative study.
Yagi T; Kanekiyo M; Ito J; Ihara R; Suzuki K; Iwata A; Iwatsubo T; Aoshima K; ;
Alzheimers Dement (N Y); 2019; 5():364-373. PubMed ID: 31440579
[TBL] [Abstract][Full Text] [Related]
19. Alzheimer Disease Signature Neurodegeneration and APOE Genotype in Mild Cognitive Impairment With Suspected Non-Alzheimer Disease Pathophysiology.
Schreiber S; Schreiber F; Lockhart SN; Horng A; Bejanin A; Landau SM; Jagust WJ;
JAMA Neurol; 2017 Jun; 74(6):650-659. PubMed ID: 28319241
[TBL] [Abstract][Full Text] [Related]
20. Effect of Pathway-Specific Polygenic Risk Scores for Alzheimer's Disease (AD) on Rate of Change in Cognitive Function and AD-Related Biomarkers Among Asymptomatic Individuals.
Xu Y; Vasiljevic E; Deming YK; Jonaitis EM; Koscik RL; Van Hulle CA; Lu Q; Carboni M; Kollmorgen G; Wild N; Carlsson CM; Johnson SC; Zetterberg H; Blennow K; Engelman CD
J Alzheimers Dis; 2023; 94(4):1587-1605. PubMed ID: 37482996
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
